1. Home
  2. TNGX vs EFSCP Comparison

TNGX vs EFSCP Comparison

Compare TNGX & EFSCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tango Therapeutics Inc.

TNGX

Tango Therapeutics Inc.

HOLD

Current Price

$8.57

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Enterprise Financial Services Corporation Depositary Shares Each Representing a 1/40th Interest in a Share of 5% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series A

EFSCP

Enterprise Financial Services Corporation Depositary Shares Each Representing a 1/40th Interest in a Share of 5% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series A

N/A

Current Price

$20.17

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TNGX
EFSCP
Founded
2014
N/A
Country
United States
United States
Employees
N/A
1256
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TNGX
EFSCP
Price
$8.57
$20.17
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$12.50
N/A
AVG Volume (30 Days)
2.4M
N/A
Earning Date
11-04-2025
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$66,501,000.00
N/A
Revenue This Year
$52.80
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
53.29
N/A
52 Week Low
$1.03
N/A
52 Week High
$11.20
N/A

Technical Indicators

Market Signals
Indicator
TNGX
EFSCP
Relative Strength Index (RSI) 43.28 59.46
Support Level $8.30 $19.67
Resistance Level $8.82 $20.19
Average True Range (ATR) 0.54 0.20
MACD -0.13 0.08
Stochastic Oscillator 15.45 96.54

Price Performance

Historical Comparison
TNGX
EFSCP

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About EFSCP Enterprise Financial Services Corporation Depositary Shares Each Representing a 1/40th Interest in a Share of 5% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series A

Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.

Share on Social Networks: